Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage
NCT ID: NCT00647556
Last Updated: 2022-08-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
30 participants
INTERVENTIONAL
2008-04-30
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
NCT01406080
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
NCT04797793
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
NCT01095640
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
NCT01522456
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
NCT03650361
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adapalene
adapalene
adapalene gel, 0.3%
applied topically once daily in the evening
tretinoin
Tretinoin
tretinoin 0.05% emollient cream
applied topically once daily in the evening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
adapalene gel, 0.3%
applied topically once daily in the evening
tretinoin 0.05% emollient cream
applied topically once daily in the evening
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically moderate to severe photodamage
Exclusion Criteria
* Subjects with diagnosis of skin cancer within 3 months of study entry
* Subjects who have had superficial chemical peels, exfoliation or microdermabrasion of the face within 3 months of study entry
* Subjects who have had botulinum toxin for facial rejuvenation within 6 months of study entry and are unwilling to refrain from botulinum toxin treatments during the study
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald W Gottschalk, MD
Role: STUDY_DIRECTOR
Galderma R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan Department of Dermatology
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US10067
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.